• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Alopecia areata following semaglutide treatment for weight loss: A case report.

作者信息

Alzahrani Wasan S, Bahkali Sadeem A, Alharthy Renad F, Alsabban Ahmad S

机构信息

College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.

King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.

出版信息

JAAD Case Rep. 2025 Jun 19;63:44-46. doi: 10.1016/j.jdcr.2025.06.012. eCollection 2025 Sep.

DOI:10.1016/j.jdcr.2025.06.012
PMID:40787040
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12329471/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa91/12329471/66f11011ef4c/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa91/12329471/8d3cd1f55a0b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa91/12329471/70eb872892ff/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa91/12329471/f11b6d9fd453/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa91/12329471/66f11011ef4c/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa91/12329471/8d3cd1f55a0b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa91/12329471/70eb872892ff/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa91/12329471/f11b6d9fd453/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa91/12329471/66f11011ef4c/gr4.jpg

相似文献

1
Alopecia areata following semaglutide treatment for weight loss: A case report.司美格鲁肽治疗减肥后出现斑秃：一例报告。
JAAD Case Rep. 2025 Jun 19;63:44-46. doi: 10.1016/j.jdcr.2025.06.012. eCollection 2025 Sep.
2
Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata.口服酪氨酸激酶3/肝细胞癌中表达的酪氨酸激酶家族激酶抑制剂芦可替尼24个月的疗效和安全性：斑秃的ALLEGRO IIb/III期和长期III期临床研究的综合分析
Br J Dermatol. 2025 Jan 24;192(2):215-227. doi: 10.1093/bjd/ljae365.
3
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment.在两项III期试验中，巴瑞替尼治疗重度斑秃成人患者长达4年（中位治疗时间2.3年）的安全性。
Am J Clin Dermatol. 2025 Apr 11. doi: 10.1007/s40257-025-00932-0.
4
Treatments for alopecia areata: a network meta-analysis.斑秃治疗方法的网状荟萃分析。
Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD013719. doi: 10.1002/14651858.CD013719.pub2.
5
Interventions for alopecia areata.斑秃的干预措施。
Cochrane Database Syst Rev. 2008 Apr 16(2):CD004413. doi: 10.1002/14651858.CD004413.pub2.
6
Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review.评估斑秃的现有和新型JAK抑制剂：一项叙述性综述
Dermatol Ther (Heidelb). 2025 Aug 12. doi: 10.1007/s13555-025-01517-9.
7
Alopecia areata with white hair regrowth: case report and review of poliosis.斑秃伴白发再生：病例报告及白发症综述
Dermatol Online J. 2014 Sep 16;20(9):13030/qt1xk5b26v.
8
The Alopecia Areata Severity and Morbidity Index (ASAMI) Study: Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity.斑秃严重度和发病率指数（ASAMI）研究：全球专家共识关于斑秃严重度决定因素的结果。
JAMA Dermatol. 2024 Mar 1;160(3):341-350. doi: 10.1001/jamadermatol.2023.5869.
9
Alopecia areata: A multifactorial autoimmune condition.斑秃：一种多因素自身免疫性疾病。
J Autoimmun. 2019 Mar;98:74-85. doi: 10.1016/j.jaut.2018.12.001. Epub 2018 Dec 15.
10
Alteration in hair texture following regrowth in alopecia areata: a case report.斑秃再生后毛发质地的改变：一例报告
Arch Dermatol. 2011 Nov;147(11):1297-9. doi: 10.1001/archdermatol.2011.192. Epub 2011 Jul 18.

本文引用的文献

1
Skin-Related Adverse Reactions Induced by Oral Antidiabetic Drugs-A Review of Literature and Case Reports.口服抗糖尿病药物引起的皮肤相关不良反应——文献综述与病例报告
Pharmaceuticals (Basel). 2024 Jun 27;17(7):847. doi: 10.3390/ph17070847.
2
Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023.与司美格鲁肽和替尔泊肽使用相关的脱发：一项使用2022年至2023年美国食品药品监督管理局不良事件报告系统（FAERS）的不成比例性分析。
J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e153-e154. doi: 10.1111/jdv.20197. Epub 2024 Jun 24.
3
GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study.
用于肥胖但无糖尿病患者减重的胰高血糖素样肽-1受体激动剂：一项基于生存获益-危害的建模研究
EClinicalMedicine. 2024 May 27;73:102661. doi: 10.1016/j.eclinm.2024.102661. eCollection 2024 Jul.
4
Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity.司美格鲁肽和利拉鲁肽作为肥胖治疗选择的分子机制
Front Nutr. 2024 Apr 29;11:1398059. doi: 10.3389/fnut.2024.1398059. eCollection 2024.
5
Dermatologic findings associated with semaglutide use: A scoping review.与司美格鲁肽使用相关的皮肤学发现：一项范围综述。
J Am Acad Dermatol. 2024 Jul;91(1):166-168. doi: 10.1016/j.jaad.2024.03.021. Epub 2024 Mar 29.
6
An overview of the genetic aspects of hair loss and its connection with nutrition.脱发的遗传学概述及其与营养的关系。
J Prev Med Hyg. 2022 Oct 17;63(2 Suppl 3):E228-E238. doi: 10.15167/2421-4248/jpmh2022.63.2S3.2765. eCollection 2022 Jun.
7
Dermatological manifestations relating to nutritional deficiencies after bariatric surgery: case report and integrative literature review.减重手术后与营养缺乏相关的皮肤科表现：病例报告和综合文献回顾。
Sao Paulo Med J. 2022 Sep-Oct;140(5):723-733. doi: 10.1590/1516-3180.2021.0616.R1.17022022.
8
Semaglutide for the treatment of obesity.司美格鲁肽用于治疗肥胖症。
Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21.
9
Safety of Semaglutide.司美格鲁肽的安全性。
Front Endocrinol (Lausanne). 2021 Jul 7;12:645563. doi: 10.3389/fendo.2021.645563. eCollection 2021.
10
Bariatric Surgery-Induced Telogen Effluvium (Bar SITE): Case Report and a Review of Hair Loss Following Weight Loss Surgery.减重手术所致休止期脱发（Bar SITE）：病例报告及减肥手术后脱发综述
Cureus. 2021 Apr 21;13(4):e14617. doi: 10.7759/cureus.14617.